Medtronic 2012 Annual Report Download - page 25

Download and view the complete annual report

Please find page 25 of the 2012 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 152

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152

The charts below set forth net sales of our Diabetes products as a percentage of our total net sales for
each of the last three fiscal years:
Customers and Competitors
The primary medical specialists who use and/or prescribe our Diabetes products are endocrinologists,
diabetologists, and internists. Our primary competitors for diabetes products are DexCom, Inc., Insulet
Corporation, Johnson & Johnson, and Roche Ltd.
Surgical Technologies
Our Surgical Technologies business develops, manufactures, and markets products and therapies to
treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In
addition, the business develops, manufactures, and markets image-guided surgery and intra-operative
imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic
surgeries. In August 2011, we completed the acquisition of two privately-held companies, PEAK
Surgical, Inc. (PEAK) and Salient Surgical Technologies, Inc. (Salient), that are focused on advanced energy
devices. PEAK is a recognized leader in the emerging field of advanced energy surgical incision technology,
and Salient is a leader in the advanced energy category for haemostatic sealing of soft tissue and bone.
The following are the principal products offered by our Surgical Technologies business:
ENT. The following products treat ENT diseases and conditions: NIM Nerve Monitoring Systems,
Fusion ENT Navigation System, Hydrodebrider Endoscopic Sinus Irrigation System, Meniett Device for
Meniere’s Disease, Pillar Procedure for Snoring and Sleep Apnea, and Repose System for Obstructive
Sleep Apnea.
Neurological Technologies. The following products treat certain neurological disorders and
conditions: Midas Rex Spine Shaver, the Midas Rex MR7 Pneumatic Platform, the Midas Rex Legend EHS
High Speed Surgical Drill, the Strata Family of Adjustable Valves for the treatment of Hydrocephalus, Duet
External Drainage & Monitoring System, the IPC System, and the Subdural Evacuating Port System.
Navigation. The following products are used in cranial, spinal, sinus, and orthopedic surgeries: the
StealthStation S7 Navigation and i7 Integrated Navigation Systems, the O-Arm 2D/3D Surgical Imaging
System, and the PoleStar Surgical MRI System.
Advanced Energy. The following products make up the Advanced Energy business: PEAK Surgery
System, a tissue dissection system that consists of the PEAK PlasmaBlade and the PULSAR Generator
and is cleared for use in a variety of settings, including ENT, plastic reconstructive and general surgery; and
the Aquamantys System, which uses patented Transcollation technology to provide haemostatic sealing of
soft tissue and bone and is cleared for use in a variety of surgical procedures, including orthopedic surgery,
spine, solid organ resection and thoracic procedures.
8
Diabetes
$1,481
All Other
$14,703
Fiscal Year 2012
(dollars in millions)
Diabetes
$1,347
All Other
$14,161
Fiscal Year 2011
(dollars in millions)
Diabetes
$1,237
All Other
$14,155
Fiscal Year 2010
(dollars in millions)
8%
92%
9%
91%
9%
91%